Vietnam Next-Generation Sequencing (NGS) Market (2026-2036)
The Vietnam next generation sequencing market is projected to reach USD 222.53 million by 2036 from an estimated USD 67.92 million in 2026, at a CAGR of 12.6% during the forecast period from 2026 to 2036. The market was valued at USD 60.40 million in 2025.
- Published
- Sep 2026
- Pages
- 142
- Format
- PDF + Excel
- Report ID
- MR-2176
- Base year
- 2025
- 2025 · BASELINE
- $60.4M
- 2036
- $222.5M
- CAGR 2026–2036
- 12.6%
2025 baseline · 2026–2036 forecast at 12.6% CAGR · hover a bar for the value
Key highlights
The Vietnam next generation sequencing market is projected to reach USD 222.53 million by 2036, growing at a CAGR of 12.6% during 2026 to 2036, driven by rapidly rising cancer incidence, the establishment of a population specific reference genome, and the continued expansion of privately funded genomic services.
According to IARC GLOBOCAN 2022 estimates, Vietnam recorded 180,480 new cancer cases and 120,184 cancer deaths, with new cases nearly doubling within a decade and forecast to rise a further 45% by 2045.
The VN1K project, conducted at the VinGroup Big Data Institute with approximately USD 4.5 million committed, analysed 1,011 individuals from 53 of Vietnam's 63 provinces and identified more than 42 million genetic variants, of which approximately 8.5 million had never been recorded in major international databases, producing the Vietnamese PanGenome Reference published in Nature Communications in July 2026.
As of 2018, approximately 13 trained medical geneticists served a population of over 90 million, and whole genome and whole exome sequencing were not routinely available for clinical care, a shortage that continues to limit how much sequencing output can be converted into reported clinical results.
By October 2022, 66 gene sequencers had been installed across Vietnamese healthcare facilities and 50 hospitals were trialling non invasive genomic methods for early cancer detection, while the largest gene sequencing centre in Southeast Asia opened in Hanoi.
Extended import licences under Vietnam's medical device registration framework lapsed on 1 July 2025, and in vitro diagnostic registration numbers issued in earlier years lost their validity, introducing product availability risk in a market wholly dependent on imported instruments and reagents.
The Law on Personal Data Protection, passed on 26 June 2025 and effective from 1 January 2026, designates health and biometric data as sensitive personal data requiring heightened safeguards and applies extraterritorially to foreign entities processing the data of Vietnamese citizens.
Circular 57/2025, issued on 31 December 2025, introduces a six group classification framework for medical device procurement, taking effect from 1 January 2027 and favouring suppliers holding United States Food and Drug Administration or European Conformity approval.
Commercial sequencing and outsourced services account for the largest share of market value in 2026 at 41.0%, while data analysis and bioinformatics is expected to register the highest CAGR of 14.6% through 2036, reflecting demand for tools that substitute for scarce interpretive staff.
Clinical applications hold the largest share of the market at 58.0% in 2026, with non invasive prenatal testing the largest single clinical application at 40.0% share and oncology the fastest growing at a CAGR of 14.5%.
Hospitals, clinical and reference laboratories represent the largest end user group at 38.0% share in 2026 and are expected to register the highest CAGR among end user segments through the forecast period.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026 to 2036 |
| Historical Year | 2024 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 12.6% |
| Format | PDF, Excel & Cloud Portal · 142 pages |
| Market Size (Value) in 2026 | USD 67.92 Million |
| Market Size (Value) in 2036 | USD 222.53 Million |
| Segments Covered | By Offering: Sample Preparation; Sequencing; Data Analysis/Bioinformatics; Commercial Sequencing/Outsourced Services. By Application: Research & Other Applications; Clinical Applications. By End User: Pharmaceutical & Biotechnology Companies; Hospitals, Clinical & Reference Laboratories; Academic & Research Institutes; Other End Users |
| Country Covered | Vietnam |
| Key Companies | Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), Novogene Co., Ltd. (China) |
| Primary Reference Sources | IARC GLOBOCAN; Vietnam Ministry of Health; Vietnam National Cancer Institute; Infrastructure and Medical Device Administration, Vietnam; Personal Data Protection authorities, Vietnam; VinBigData/VinGroup Big Data Institute publications; Nature Communications; company annual reports, investor presentations, and press releases from Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Roche, Revvity, Pacific Biosciences, Danaher, Oxford Nanopore Technologies, MGI Tech, BGI Genomics, Eurofins Scientific, and Novogene |
Report overview
Segments covered: offering, application, end user.
Clinical applications account for the largest share of market value through most of the forecast period, supported by a cancer burden that has nearly doubled within a decade and by the widening use of sequencing in prenatal and reproductive testing, while oncology represents the fastest growing clinical application as molecular tumor testing gains ground across Vietnamese hospitals.
Next generation sequencing comprises a group of high throughput technologies that determine the order of nucleotides across many DNA or RNA fragments in parallel, allowing the interrogation of targeted gene panels, whole exomes, or whole genomes within a single workflow. The Vietnam market covers revenue generated from sample preparation products, sequencing systems and consumables, data analysis software and informatics services, and commercial sequencing services supplied to organizations operating within the country, regardless of where the supplying entity is located. Revenue is attributed to Vietnam wherever the demand originates, including cases where the physical sequencing is carried out abroad under an outsourced arrangement.
Vietnam has a population of approximately 100 million, the largest in mainland Southeast Asia, supported by a primary care network of roughly 11,000 community health centres. The disease profile has shifted markedly, with the share of mortality attributable to communicable disease falling from 33% in 1996 to a projected 6% in 2026, while cancer has become the clearest illustration of the change. New cancer cases rose from around 68,000 in 2000 to more than 180,000 in 2022, nearly doubling within a decade, and genomic capability has developed rapidly from a low base, principally through private rather than public investment. By October 2022, 66 gene sequencers had been installed nationally and the largest gene sequencing centre in Southeast Asia had opened in Hanoi.
Two features distinguish the Vietnamese market from comparable markets in the region. Vietnam has no government funded national genome programme, so programme scale sequencing demand comes from commercial and institutional decisions rather than from a public budget line, and this is best illustrated by the VN1K project, funded by VinGroup rather than by the state. In addition, a substantial share of Vietnamese sequencing demand is met through outsourced arrangements rather than in house capability, which weights the market toward consumables and services and directs a portion of the value generated by Vietnamese demand toward suppliers located outside the country.
Market dynamics
8 factors across 3 forcesRapid Growth in Cancer Incidence
According to IARC GLOBOCAN 2022 estimates, Vietnam recorded 180,480 new cancer cases and 120,184 cancer deaths, equivalent to 151 new diagnoses and 99 deaths per 100,000 population, with more than 409,000 people living with cancer. New cases rose from around 68,000 in 2000 to approximately 125,000 in 2010 and to more than 180,000 today, and GLOBOCAN forecasts a further increase of approximately 45% by 2045. The five most common cancers are breast, liver, lung, colorectal, and stomach, and two of these, lung and colorectal cancer, carry established molecular testing requirements that support tumor mutation testing demand.
Establishment of a Population Specific Reference Genome
The VN1K project analysed 1,011 Vietnamese individuals from 53 of the country's 63 provinces and cities, identified more than 42 million genetic variants of which approximately 8.5 million had never been recorded in major international genomic databases, and produced the Vietnamese PanGenome Reference, published in Nature Communications in July 2026. Before this resource, the principal reference for Vietnamese genetic variation comprised just 99 individuals from a single ethnic group studied within the 1000 Genomes Project, so the new reference materially improves diagnostic yield and reduces the interpretive burden carried by a small pool of trained staff.
Expansion of Privately Funded Genomic Services
Genomic capability in Vietnam has expanded principally through private investment rather than public appropriation. VinGroup committed approximately USD 4.5 million to the VN1K sequencing work, and the largest gene sequencing centre in Southeast Asia opened in Hanoi. Non invasive prenatal testing, expanded carrier screening, and oncology panel testing are supplied predominantly by private laboratories to patients paying directly, and this volume has been substantial enough that one study derived more than 8 million single nucleotide polymorphisms from the prenatal testing data of 2,683 pregnant women.
Table of contents
10 chapters · 189 sections · 142 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Offering | Commercial sequencing and outsourced services | Data Analysis and Bioinformatics |
| By Application | Non-invasive prenatal testing (NIPT) | Oncology |
| By End User | Hospitals, Clinical and Reference Laboratories | — |
By Offering
- Commercial sequencing and outsourced services account for the largest share of the market, driven by the outsourcing of not only sequencing capabilities but also data interpretation, a capability that Vietnamese institutions often lack.
- Data analysis and bioinformatics is expected to register the highest CAGR as software and outsourced analysis substitute for interpretive staff that institutions cannot readily recruit.
By Application
- Clinical Applications Hold the Largest Share, Oncology Grows Fastest
- Within this segment, non-invasive prenatal testing (NIPT) accounts for the largest share, driven by direct out-of-pocket payment by parents and the relatively limited interpretive requirements, which focus on three defined trisomies.
- Meanwhile, oncology is expected to experience the highest growth rate, as tumor mutation testing expands from a comparatively smaller existing base.
By End User
- Hospitals, Clinical and Reference Laboratories Lead in 2026
- Hospitals, clinical laboratories, and reference laboratories account for the largest share of the market among end-user segments.
- Private reference laboratories represent a substantial portion of this segment, as clinical sequencing is funded predominantly through direct patient payments.
Competitive landscape
The Vietnam next generation sequencing market is consolidated and led by international suppliers, none of which manufactures within the country. In 2025, Illumina, Inc., Thermo Fisher Scientific Inc., MGI Tech Co., Ltd., QIAGEN N.V., and BGI Genomics Co., Ltd. collectively accounted for a major share of this market, with Illumina holding the leading position at an estimated 20% to 24% share, followed by Thermo Fisher Scientific at 11% to 15%, MGI Tech at 8% to 11%, QIAGEN at 6% to 8%, and BGI Genomics at 5% to 7%.
Some of the prominent players operating in the Vietnam next generation sequencing market include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China), among local distributors and sequencing service providers operating within Vietnam.
- —
Illumina completed its acquisition of SomaLogic from Standard BioTools in January 2026 for USD 350 million in cash plus up to USD 75 million in milestones, extending its position from genomics into proteomics, and launched the MiSeq i100 Series completing sequencing runs in as little as four hours.
- —
Thermo Fisher Scientific completed its acquisition of Olink for USD 3.1 billion in 2024 and its USD 4.0 billion acquisition of Solventum's Purification and Filtration business in September 2025.
- —
QIAGEN completed its acquisition of Parse Biosciences in December 2025 and launched the QIAseq xHYB Long Read Panels in July 2025, extending target enrichment content to long read sequencing platforms.
- —
MGI Tech announced the acquisition of STOmics and CycloneSEQ in March 2026, bringing spatial multi omics and long read nanopore sequencing in house, and launched the DNBSEQ T7+ high throughput sequencer in September 2025, delivering more than 14 terabases of data in 24 hours.
- —
BGI Genomics participated in the launch of the Southeast Asian Alliance for the Prevention and Treatment of Thalassemia in Chiang Mai in November 2025 and set out its collaboration with APEC member economies in April 2026.
- —
F. Hoffmann La Roche launched the AXELIOS sequencing platform commercially in 2026 based on its sequencing by expansion chemistry, re entering a field it had previously exited.
- —
Oxford Nanopore Technologies introduced a short fragment mode supporting fragments as short as 200 to 500 base pairs, addressing formalin fixed paraffin embedded oncology material common in Vietnamese sampling.
- —
Vietnam's Ministry of Health issued Consolidated Document No. 08/VBHN BYT on 6 March 2026, merging Decree 98/2021 and its amendments into a single reference text governing medical device registration.
- —
Law No. 91/2025/QH15 on Personal Data Protection was passed by the National Assembly on 26 June 2025 and took effect on 1 January 2026, together with implementing Decree 356/2025/ND CP.
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Agilent Technologies, Inc. (U.S.)
- F. Hoffmann La Roche Ltd. · Switzerland
- Revvity, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
- Danaher Corporation (U.S.)
- Oxford Nanopore Technologies plc (U.K.)
- MGI Tech Co., Ltd. · China
- BGI Genomics Co., Ltd. · China
- Eurofins Scientific SE · Luxembourg
- Novogene Co., Ltd. · China
Frequently asked questions
The Vietnam next generation sequencing market size is estimated at USD 67.92 million in 2026.
Cite this report
Meticulous Research. (2026). Vietnam Next-Generation Sequencing (NGS) Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2176). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/vietnam-next-generation-sequencing-market-6859